{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0800504,73,MONDO:0800504,176,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0800504","source":"MONDO:0800504|idiopathic pulmonary fibrosis","targets":["NCT00625079|Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00625469|Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00637065|Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01321996|68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT01382368|Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02579603|Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF|COMPLETED|PHASE4|INTERVENTIONAL","NCT02598193|Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE4|INTERVENTIONAL","NCT02606877|A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination|COMPLETED|PHASE4|INTERVENTIONAL","NCT02788474|Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment|COMPLETED|PHASE4|INTERVENTIONAL","NCT03503188|Digital Auscultation Test - IPF Data Collection|COMPLETED|PHASE4|INTERVENTIONAL","NCT03717012|Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE4|INTERVENTIONAL","NCT03939520|Management of Progressive Disease in Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00047645|A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00071461|Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00075998|The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE3|INTERVENTIONAL","NCT00076635|An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF|TERMINATED|PHASE3|INTERVENTIONAL","NCT00105183|EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection|COMPLETED|PHASE3|INTERVENTIONAL","NCT00131274|Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00203697|Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00287716|Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00287729|Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00391443|BUILD 3: Bosentan Use in Interstitial Lung Disease|COMPLETED|PHASE3|INTERVENTIONAL","NCT00600028|Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide|COMPLETED|PHASE3|INTERVENTIONAL","NCT00631475|Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443|COMPLETED|PHASE3|INTERVENTIONAL","NCT00662038|Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00768300|(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF|TERMINATED|PHASE3|INTERVENTIONAL","NCT00879229|ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT00957242|AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT00981747|Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT01366209|Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01619085|Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT01777737|Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole|TERMINATED|PHASE3|INTERVENTIONAL","NCT01979952|Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02460588|Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT02739165|Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT02759120|CleanUP IPF for the Pulmonary Trials Cooperative|TERMINATED|PHASE3|INTERVENTIONAL","NCT02802345|Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment|COMPLETED|PHASE3|INTERVENTIONAL","NCT03208933|Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).|COMPLETED|PHASE3|INTERVENTIONAL","NCT03711162|A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care|TERMINATED|PHASE3|INTERVENTIONAL","NCT03733444|A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care|TERMINATED|PHASE3|INTERVENTIONAL","NCT03955146|Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04300920|Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04419558|Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04429516|Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough|COMPLETED|PHASE3|INTERVENTIONAL","NCT04497831|Morphine for Dyspnea in Pulmonary Fibrosis|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04552899|A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT04594707|A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT04708782|Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT04905693|Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease|ENROLLING_BY_INVITATION|PHASE3|INTERVENTIONAL","NCT04965298|Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole|RECRUITING|PHASE3|INTERVENTIONAL","NCT05255991|Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT05321069|A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE3|INTERVENTIONAL","NCT06003426|A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT06037408|The Effect of N115 on Coughing in IPF Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT06125327|SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06238622|A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast|RECRUITING|PHASE3|INTERVENTIONAL","NCT07082842|Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07284602|Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07299695|Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT00047658|A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT00080223|Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT00162760|Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide|COMPLETED|PHASE2|INTERVENTIONAL","NCT00189176|Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00262405|Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT00463983|Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00532233|SD, IL-13 Production Rate in IPF|COMPLETED|PHASE2|INTERVENTIONAL","NCT00703339|Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE2|INTERVENTIONAL","NCT00705133|Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension|COMPLETED|PHASE2|INTERVENTIONAL","NCT00903331|Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT01136174|Safety and PK Study of BIBF 1120 in Japanese Patients With IPF|COMPLETED|PHASE2|INTERVENTIONAL","NCT01203943|A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01214187|Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT01262001|Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT01265888|Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.|COMPLETED|PHASE2|INTERVENTIONAL","NCT01266135|Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01266317|Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01346930|Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT01371305|STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT01504334|Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)|UNKNOWN|PHASE2|INTERVENTIONAL","NCT01524068|A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT01529853|To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT01629667|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|TERMINATED|PHASE2|INTERVENTIONAL","NCT01759511|Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01766817|Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT01769196|Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)|TERMINATED|PHASE2|INTERVENTIONAL","NCT01872689|A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT01890265|Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT02036580|D2212C00002 J-Phase II Study|COMPLETED|PHASE2|INTERVENTIONAL","NCT02036970|Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT|COMPLETED|PHASE2|INTERVENTIONAL","NCT02048644|Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT02055456|Nandrolone Decanoate in the Treatment of Telomeropathies|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02085018|Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT02135380|Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis|UNKNOWN|PHASE1/PHASE2|INTERVENTIONAL","NCT02136992|Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT02168530|A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT02257177|RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT02345070|Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT02477709|A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|COMPLETED|PHASE2|INTERVENTIONAL","NCT02502097|A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)|COMPLETED|PHASE2|INTERVENTIONAL","NCT02503657|Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis|COMPLETED|PHASE2|INTERVENTIONAL"]}]}